Cybin Inc. (FRA:R7E)
Germany · Delayed Price · Currency is EUR | Market Cap | 352.17M +113.3% |
| Revenue (ttm) | n/a |
| Net Income | -104.94M |
| EPS | -3.81 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30 |
| Open | 4.75 |
| Previous Close | 5.14 |
| Day's Range | 4.75 - 5.61 |
| 52-Week Range | 3.08 - 8.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 1, 2026 |
About Cybin
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and... [Read more]
News
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping min...
Helus Pharma prices 10.31M common shares at $4.85 in public offering
Helus Pharma (HELP) is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the company at an offering price of $4.85 per…
Helus Pharma says enrollment in APPROACH Phase 3 trial ‘progressing as planned’
Helus Pharma (HELP) announced that enrollment in the APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder is progressing as planned and has surpassed…
Helus Pharma™ Announces US$50 Million Underwritten Offering
NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping min...
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment -
Cybin Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
The summit featured updates on novel serotonergic agonists for MDD and GAD, with HLP003 in phase III and top-line data expected by year-end. The company leverages established psychiatric infrastructure and maintains strong FDA engagement, targeting NDA submission in 2028.
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
NEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serot...
Cybin Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing novel serotonergic agonists for mental health, with a lead MDD program showing strong efficacy and durability, and a second program targeting anxiety. Regulatory support is robust, commercialization prospects are strong due to unique dosing and IP, and key phase III data is expected in Q4.
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
Eric So, Interim CEO, to participate in a fireside chat on Thursday, June 4 at 2:35 p.m. EDT NEW YORK and TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a cli...
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
NEW YORK & TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 28, 2026, by Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP), please note references to Veterans...
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
Eric So, Interim CEO, to appear on panel entitled “The Next Wave of Health Innovation,” on May 4, 2026 NEW YORK and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: H...
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
NEW YORK & TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel seroton...
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
NEW YORK and TORONTO, April 23, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serot...
How Trump's psychedelics executive order could unlock stalled cannabis reform
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status,...
Helus ‘welcomes’ Executive Order for accelerating psychedelic research
Helus Pharma (HELP) welcomed the White House Executive Order aimed at accelerating research, regulatory pathways, and patient access to psychedelic treatments. “The Executive Order reflects growing re...
Helus Pharma announces Cola is stepping down as CEO, appoints So as Interim CEO
Helus Pharma (HELP) announced that Michael Cola is stepping down as Chief Executive Officer, effective immediately, at the request of the Board of Directors. The Board has appointed Co-founder and…
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serot...
Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer
This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 20...
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic dr...
Helus Pharma appoints Kramer as Senior Vice President, Medical Affairs
Helus Pharma (HELP) announced the appointment of Dr. Ken Kramer, PhD as Senior Vice President, Medical Affairs, effective immediately. Most recently, Kramer served as Vice President and Head of Medica...
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
NEW YORK and TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel sero...
Helus Pharma initiated with a Buy at TD Cowen
TD Cowen analyst Ritu Baral initiated coverage of Helus Pharma (HELP) with a Buy rating and $8 price target The firm believes the company’s positive Phase 2 adjunct major depressive…
Cybin Slides: Corporate presentation
Cybin has posted slides in relation to its latest quarterly earnings report, which was published on March 27, 2026.
Helus Pharma appoints Conwell as Chief People Officer
Helus Pharma (HELP) announced the appointment of Jill Conwell as Chief People Officer, effective immediately. Conwell has held senior leadership roles at Aclaris Therapeutics (ACRS), Idera Pharmaceuti...
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
NEW YORK and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel sero...